These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16933470)

  • 1. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.
    Judson MA; Silvestri J; Hartung C; Byars T; Cox CE
    Sarcoidosis Vasc Diffuse Lung Dis; 2006 Mar; 23(1):51-7. PubMed ID: 16933470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic management of pulmonary sarcoidosis.
    Fazzi P
    Am J Respir Med; 2003; 2(4):311-20. PubMed ID: 14719997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy.
    Gottlieb JE; Israel HL; Steiner RM; Triolo J; Patrick H
    Chest; 1997 Mar; 111(3):623-31. PubMed ID: 9118698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study.
    Fang C; Zhang Q; Wang N; Jing X; Xu Z
    Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(3):217-227. PubMed ID: 32476957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial.
    Judson MA; Baughman RP; Costabel U; Mack M; Barnathan ES
    Respir Med; 2014 Jan; 108(1):189-94. PubMed ID: 24361164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
    Carlesimo M; Giustini S; Rossi A; Bonaccorsi P; Calvieri S
    J Am Acad Dermatol; 1995 May; 32(5 Pt 2):866-9. PubMed ID: 7722046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids.
    Fazzi P; Manni E; Cristofani R; Cei G; Piazza S; Calabrese R; Antonelli A; Siciliano G; Barachini P; Carpi A
    Biomed Pharmacother; 2012 Jun; 66(4):300-7. PubMed ID: 22494798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
    Friedman MA; Le B; Stevens J; Desmarais J; Seifer D; Ogle K; Choi D; Harrington CA; Jackson P; Rosenbaum JT
    Lung; 2021 Apr; 199(2):147-153. PubMed ID: 33825964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids for pulmonary sarcoidosis.
    Paramothayan NS; Jones PW
    Cochrane Database Syst Rev; 2000; (2):CD001114. PubMed ID: 10796598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations.
    McKinzie BP; Bullington WM; Mazur JE; Judson MA
    Am J Med Sci; 2010 Jan; 339(1):1-4. PubMed ID: 19996733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study.
    Kahlmann V; Janssen Bonás M; Moor CC; van Moorsel CHM; Kool M; Kraaijvanger R; Grutters JC; Overgaauw M; Veltkamp M; Wijsenbeek MS;
    BMC Pulm Med; 2020 Oct; 20(1):271. PubMed ID: 33076885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
    Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
    Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids.
    Aggarwal AN; Sahu KK; Gupta D
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Aug; 33(2):124-9. PubMed ID: 27537714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis.
    Kaye O; Palazzo E; Grossin M; Bourgeois P; Kahn MF; Malaise MG
    Br J Rheumatol; 1995 Jul; 34(7):642-4. PubMed ID: 7670783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.
    Baughman RP; Winget DB; Lower EE
    Sarcoidosis Vasc Diffuse Lung Dis; 2000 Mar; 17(1):60-6. PubMed ID: 10746262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.
    Hayes K; Niewoehner J; Rice JB; Downes N; Hagopian E; Ma I; Wan GJ
    Adv Ther; 2023 Nov; 40(11):4999-5015. PubMed ID: 37728695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid refractory sarcoidosis.
    Goldman C; Judson MA
    Respir Med; 2020 Sep; 171():106081. PubMed ID: 32658838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.
    Judson MA; Chaudhry H; Louis A; Lee K; Yucel R
    Respir Med; 2015 Apr; 109(4):526-31. PubMed ID: 25698652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: a pilot study.
    Knopf A; Lahmer T; Chaker A; Stark T; Hofauer B; Pickhard A; Thürmel K; Bas M
    Head Neck; 2013 May; 35(5):715-9. PubMed ID: 22730039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.